Bridgebio Oncology Therapeutics Inc (BBOT) Stock Price, Quote & News

Company Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecul...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 405 4770

Website: bbotx.com

Address:

256 East Grand Avenue, Suite 104, South San Francisco, United States

PhishTourFunds Sep. 17 at 11:11 PM

$BBOT RSI now under 20

0 · Reply

PLATINUM_TRADES Sep. 17 at 3:21 PM

$BBOT I told u this was a gift.. A little wait but money coming in 😜😜

0 · Reply

PLATINUM_TRADES Sep. 15 at 5:01 PM

$BBOT If you're in the Pitt.. You're banking... Way more to come imo bounce has begun🥇🥇

0 · Reply

PhishTourFunds Sep. 15 at 2:17 PM

$BBOT Everyone getting paid out of the SPAC trough ~ company has cash runway through 2027

0 · Reply

PLATINUM_TRADES Sep. 15 at 2:15 PM

$BBOT Thank you.. What a gift 🎁 you

0 · Reply

PLATINUM_TRADES Sep. 15 at 12:50 PM

$BBOT Big dump but they always bounce..... $5.19 High yesterday to break today for more 🚨 🚨

0 · Reply

PhishTourFunds Sep. 14 at 11:16 PM

$BBOT 👁️👁️ “Dafuq goin on ova cheer?”

0 · Reply

gobio Sep. 13 at 8:47 PM

$BBOT https://finance.yahoo.com/healthcare/articles/bridgebio-oncology-therapeutics-bbot-bets-074039253.html

0 · Reply

PhishTourFunds Sep. 11 at 6:18 PM

$BBOT Shorts PILING in here 🤯

0 · Reply

PhishTourFunds Sep. 11 at 5:58 PM

$BBOT Already 2x daily volume average 😮

0 · Reply

BridgeBio Oncology Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

2026-09-11T10:55:21.000Z - 11 days ago

JPMorgan cuts BridgeBio target, sees buying opportunity on selloff

2026-09-10T11:40:34.000Z - 12 days ago

BridgeBio Oncology price target lowered to $27 from $39 at Leerink

2026-09-09T12:50:19.000Z - 13 days ago

BridgeBio Oncology price target lowered to $22 from $24 at Raymond James

2026-09-09T11:41:42.000Z - 13 days ago

BridgeBio Oncology price target lowered to $15 from $23 at Stifel

2026-09-09T11:16:42.000Z - 13 days ago

BridgeBio Oncology price target lowered to $20 from $23 at Canaccord

Sep 8, 2026, 4:05 PM EDT - 14 days ago

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

Sep 8, 2026, 8:00 AM EDT - 14 days ago

BridgeBio Oncology Therapeutics Slides: Corporate presentation

Sep 1, 2026, 4:05 PM EDT - 21 days ago

BBOT to Participate in Upcoming Investor Healthcare Conferences

Sep 1, 2026, 8:00 AM EDT - 21 days ago

BridgeBio Oncology Therapeutics Registration statement: Registration filing

2026-08-16T13:20:56.000Z - 5 weeks ago

BridgeBio Oncology price target lowered to $25 from $27 at JPMorgan

Aug 11, 2026, 4:40 PM EDT - 6 weeks ago

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 11, 2026, 4:05 PM EDT - 6 weeks ago

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Aug 11, 2026, 4:00 PM EDT - 6 weeks ago

BridgeBio Oncology Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 6 weeks ago

BridgeBio Oncology Therapeutics Quarterly report: Q2 2026

2026-07-08T09:50:16.000Z - 2 months ago

BridgeBio Oncology initiated with an Overweight at JPMorgan

2026-06-22T11:33:45.000Z - 3 months ago

BridgeBio Oncology assumed with an Outperform at Oppenheimer

Jun 16, 2026, 4:00 PM EDT - 3 months ago

BridgeBio Oncology Therapeutics Transcript: AGM 2026

May 12, 2026, 5:03 PM EDT - 4 months ago

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 12, 2026, 4:00 PM EDT - 4 months ago

BridgeBio Oncology Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 4 months ago

BridgeBio Oncology Therapeutics Quarterly report: Q1 2026

2026-05-11T13:08:56.000Z - 4 months ago

BridgeBio Oncology initiated with a Buy at Canaccord

2026-05-11T09:23:47.000Z - 4 months ago

BridgeBio Oncology initiated with a Buy at Canaccord

Apr 28, 2026, 8:00 AM EDT - 4 months ago

BridgeBio Oncology Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

BridgeBio Oncology Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 4:05 PM EDT - 5 months ago

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

2026-04-22T14:09:42.000Z - 5 months ago

BridgeBio Oncology appoints Pedro Beltran as CEO, Idan Elmelech as COO

Apr 22, 2026, 9:00 AM EDT - 5 months ago

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Apr 21, 2026, 5:30 PM EDT - 5 months ago

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

2026-04-20T20:27:18.000Z - 5 months ago

BridgeBio Oncology announces FDA Fast Track Designation for BBO-11818

Apr 20, 2026, 4:06 PM EDT - 5 months ago

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

Mar 18, 2026, 4:05 PM EDT - 6 months ago

BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 10, 2026, 10:00 AM EDT - 6 months ago

BridgeBio Oncology Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-06T15:26:19.000Z - 6 months ago

BridgeBio Oncology announces publication of preclinical data on BBO-11818

Mar 6, 2026, 10:07 AM EST - 6 months ago

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

2026-03-06T11:15:39.000Z - 6 months ago

BridgeBio Oncology price target raised to $29 from $27 at H.C. Wainwright

Mar 5, 2026, 4:05 PM EST - 6 months ago

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

HLXB

Mar 5, 2026, 4:00 PM EST - 6 months ago

BridgeBio Oncology Therapeutics Annual report: Q4 2025

Mar 5, 2026, 4:00 PM EST - 6 months ago

BridgeBio Oncology Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 10:40 AM EST - 6 months ago

BridgeBio Oncology Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-10T21:22:27.000Z - 7 months ago

BridgeBio Oncology initiated with a Buy at Stifel

Jan 12, 2026, 8:15 PM EST - 8 months ago

BridgeBio Oncology Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-09T11:30:32.000Z - 8 months ago

BridgeBio Oncology initiated with an Outperform at Raymond James

2026-01-08T12:51:12.000Z - 8 months ago

BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley

Jan 7, 2026, 8:30 AM EST - 8 months ago

BridgeBio Oncology Therapeutics Transcript: Study Update

Jan 7, 2026, 8:30 AM EST - 8 months ago

BridgeBio Oncology Therapeutics Press release: Study Update

Jan 7, 2026, 8:30 AM EST - 8 months ago

BridgeBio Oncology Therapeutics Slides: Study Update

Jan 7, 2026, 7:00 AM EST - 8 months ago

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

Dec 16, 2025, 4:05 PM EST - 9 months ago

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:05 PM EST - 9 months ago

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2025, 4:05 PM EST - 9 months ago

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

Dec 3, 2025, 9:35 AM EST - 9 months ago

BridgeBio Oncology Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:00 PM EST - 9 months ago

BridgeBio Oncology Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 4:05 PM EST - 10 months ago

BBOT to Participate in Upcoming December Investor Healthcare Conferences

Nov 17, 2025, 9:30 AM EST - 10 months ago

BridgeBio Oncology Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:05 PM EST - 10 months ago

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

HLXB

Nov 12, 2025, 7:00 AM EST - 10 months ago

BridgeBio Oncology Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

BridgeBio Oncology Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 4:05 PM EST - 10 months ago

BBOT to Participate in the Jefferies Global Healthcare Conference in London

Oct 30, 2025, 5:45 PM EDT - 10 months ago

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Oct 25, 2025, 12:30 PM EDT - 11 months ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

Oct 23, 2025, 4:05 PM EDT - 11 months ago

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 11 months ago

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 8, 2025, 7:45 AM EDT - 1 year ago

BridgeBio Oncology Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 5, 2025, 7:00 AM EDT - 1 year ago

BridgeBio Oncology Therapeutics Slides: Corporate Presentation

Sep 4, 2025, 8:35 AM EDT - 1 year ago

BridgeBio Oncology Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 8:00 AM EDT - 1 year ago

BridgeBio Oncology Therapeutics Registration statement: Registration Filing

Aug 20, 2025, 8:00 AM EDT - 1 year ago

BBOT to Participate in Upcoming September Investor Healthcare Conferences

Aug 11, 2025, 4:30 PM EDT - 1 year ago

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

HLXB

PhishTourFunds Sep. 17 at 11:11 PM

$BBOT RSI now under 20

0 · Reply

PLATINUM_TRADES Sep. 17 at 3:21 PM

$BBOT I told u this was a gift.. A little wait but money coming in 😜😜

0 · Reply

PLATINUM_TRADES Sep. 15 at 5:01 PM

$BBOT If you're in the Pitt.. You're banking... Way more to come imo bounce has begun🥇🥇

0 · Reply

PhishTourFunds Sep. 15 at 2:17 PM

$BBOT Everyone getting paid out of the SPAC trough ~ company has cash runway through 2027

0 · Reply

PLATINUM_TRADES Sep. 15 at 2:15 PM

$BBOT Thank you.. What a gift 🎁 you

0 · Reply

PLATINUM_TRADES Sep. 15 at 12:50 PM

$BBOT Big dump but they always bounce..... $5.19 High yesterday to break today for more 🚨 🚨

0 · Reply

PhishTourFunds Sep. 14 at 11:16 PM

$BBOT 👁️👁️ “Dafuq goin on ova cheer?”

0 · Reply

gobio Sep. 13 at 8:47 PM

$BBOT https://finance.yahoo.com/healthcare/articles/bridgebio-oncology-therapeutics-bbot-bets-074039253.html

0 · Reply

PhishTourFunds Sep. 11 at 6:18 PM

$BBOT Shorts PILING in here 🤯

0 · Reply

PhishTourFunds Sep. 11 at 5:58 PM

$BBOT Already 2x daily volume average 😮

0 · Reply

SilentSniper Sep. 11 at 2:15 PM

$BBOT added some $5.20s

0 · Reply

notreload_ai Sep. 11 at 12:10 PM

$BBOT dropped ~38% in two days. Stifel, Leerink, Canaccord, and JPMorgan lowered targets but did not downgrade ratings. JPMorgan sees a disconnect vs pipeline value. https://notreload.xyz/xy/bbot-stock-slides-as-investors-price-a-smaller-opportunity/

0 · Reply

Windy007 Sep. 11 at 11:16 AM

$BBOT JPMorgan cuts BridgeBio target, sees buying opportunity on selloff. JPMorgan lowered the firm’s price target on BridgeBio Oncology (BBOT) to $23 from $25 and keeps an Overweight rating on the shares. The firm updated the company’s model following the clinical data on BBO-8520 and its portfolio reprioritization decisions. The corresponding 40% share selloff is overdone and creates a buying opportunity, the analyst tells investors in a research note. At current levels, JPMorgan sees a “disconnect” between BridgeBio shares and the probability-adjusted value of its pipeline. The firm estimates peak sales of $5B in unadjusted revenues if the drug is partnered outside the U.S. even without front-line lung cancer in the 8520 program and without breast cancer in the 10203 program.

0 · Reply

TNNStockAnalysisNews Sep. 11 at 2:52 AM

Top Losing Stocks Today (Sep 10, 2026): $SUNE Closed at $3.68, Down 18.40% $NXXT Closed at $0.158, Down 18.32% $VNCE Closed at $5.26, Down 17.55% $BBOT Closed at $5.60, Down 17.10% $LAKE Closed at $9.30, Down 15.99% https://truthsandnews.com/markets/top-losing-stocks-today-sept-10-2026-biggest-drops

0 · Reply

dcrown Sep. 10 at 8:10 PM

$BBOT it’s a falling knife , bottom maybe $3-$4

1 · Reply

PhishTourFunds Sep. 10 at 3:11 AM

$BBOT Awful M&A 🎯 kinda action…6x daily average volume today 👁️👁️

1 · Reply

shoshone Sep. 9 at 9:10 PM

$BBOT wtf

0 · Reply

prismmarketview Sep. 9 at 8:49 PM

A broad selloff Wednesday: 25 of 27 PRISM indexes closed lower, with global health (-4.52%), space (-4.16%) and EV (-3.71%) hit hardest. Only psychedelics (+2.80%) and oil & gas (+0.93%) finished green. Biggest single-stock moves: $IRD +32.03% and $SKYE +18.62% led the gainers, while $BBOT -23.76%, $WW -16.95% and $XPOF -16.04% led the decliners. Full board below. Index detail at http://prismmarketview.com

1 · Reply

dcrown Sep. 9 at 8:22 PM

$BBOT opting to de-prioritize its first-line cancer drug development and ill prepared , dead money for quite some time now

1 · Reply

Merlintrader Sep. 9 at 2:16 PM

$BBOT — New Phase 1 BBO-8520 Data and a Strategic Focus on Combination Therapies https://www.merlintrader.com/bridgebio-oncology-bbot-stock-hub/

0 · Reply

ihatemyjob77 Sep. 8 at 4:56 PM

$BBOT Appears to have gone completely under the radar. They are attended 3 separate events within a week, the first of which is tomorrow. readouts from all 3 assets imminent.

1 · Reply

G101SPM Sep. 2 at 1:09 PM

#DILUTION BridgeBio Oncology Therapeutics ($BBOT) files for $500 mln mixed securities shelf offering Perella Weinberg Partners ($PWP) files prospectus supplement; relates to the offer and sale of up to 1,127,529 shares of common stock by selling holders ($AIIO) files for 13,568,510 Class B ordinary share offering by selling shareholders $BW LPG (BWLP) places $300 mln convertible bond offering due 2031

1 · Reply

Market Cap	382.43M
Revenue (ttm)	0.00
Net Income (ttm)	-134.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	508,575
Avg Vol	435,398
Day's Range	N/A - N/A
Shares Out	80.17M
Stochastic %K	2%
Beta	0.38
Analysts	Strong Sell
Price Target	$22.20